RJA
ESPR

Raymond James & Associates’s Esperion Therapeutics ESPR Stock Holding History

Raymond James & Associates’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$83.6K Sell
50,657
-6,220
-11% -$12.6K ﹤0.01% 3803
2024
Q2 		$126K Hold
56,877
– – ﹤0.01% 3698
2024
Q1 		$152K Buy
56,877
+17,527
+45% +$42.6K ﹤0.01% 3672
2023
Q4 		$118K Buy
39,350
+17,636
+81% +$22.9K ﹤0.01% 3624
2023
Q3 		$21.3K Buy
21,714
+4,578
+27% +$6.62K ﹤0.01% 3732
2023
Q2 		$23.8K Buy
17,136
+2,798
+20% +$3.91K ﹤0.01% 3766
2023
Q1 		$22.8K Sell
14,338
-23,590
-62% -$122K ﹤0.01% 3788
2022
Q4 		$236K Buy
+37,928
New +$271K ﹤0.01% 3354
2022
Q3 		– Sell
-10,840
Closed -$69K – 4001
2022
Q2 		$69K Buy
+10,840
New +$61.5K ﹤0.01% 3745
2021
Q2 		– Sell
-22,721
Closed -$637K – 4120
2021
Q1 		$637K Buy
22,721
+11,161
+97% +$329K ﹤0.01% 2832
2020
Q4 		$301K Buy
11,560
+2,667
+30% +$79.9K ﹤0.01% 3116
2020
Q3 		$331K Buy
8,893
+3,928
+79% +$156K ﹤0.01% 2891
2020
Q2 		$255K Buy
+4,965
New +$208K ﹤0.01% 3010
2020
Q1 		– Sell
-3,975
Closed -$237K – 3559
2019
Q4 		$237K Buy
+3,975
New +$179K ﹤0.01% 3237
2019
Q3 		– Sell
-5,060
Closed -$235K – 3637
2019
Q2 		$235K Buy
+5,060
New +$238K ﹤0.01% 3145
2018
Q4 		– Sell
-6,699
Closed -$297K – 3593
2018
Q3 		$297K Buy
+6,699
New +$308K ﹤0.01% 3038
2017
Q3 		– Sell
-5,200
Closed -$241K – 3424
2017
Q2 		$241K Buy
+5,200
New +$191K ﹤0.01% 2873

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Raymond James & Associates's ESPR Position: Q3 2024 in Review

Raymond James & Associates reduced its Esperion Therapeutics (ESPR) stake by 11% in Q3 2024, selling an estimated $12.6K and leaving 50,657 shares worth $83.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3803.

Raymond James & Associates first reported a position in ESPR in Q2 2017 and has held it in 17 quarters since. The position peaked at $637K in Q1 2021. 183 funds tracked by Wall St. Rank hold ESPR as of Q3 2024.

  • Raymond James & Associates held 50,657 shares of Esperion Therapeutics worth $83.6K as of Q3 2024.
  • Raymond James & Associates sold 6,220 Esperion Therapeutics shares in Q3 2024, an estimated $12.6K.
  • Esperion Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3803 holding.
  • Raymond James & Associates first reported a position in Esperion Therapeutics in Q2 2017 and has held it in 17 quarters since.
  • Raymond James & Associates's Esperion Therapeutics position peaked at $637K in Q1 2021.
  • 183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.